Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GDTC NASDAQ:IMNN NASDAQ:PHXM NASDAQ:VCNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDTCCytoMed Therapeutics$0.78+7.9%$1.02$0.68▼$3.68$8.56M-0.188,106 shs119,865 shsIMNNImunon$2.72-0.4%$3.01$2.52▼$41.22$10.88M2.0435,287 shs18,948 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AVCNXVaccinex$1.01$0.98$0.31▼$1.50$2.63M1.13,345 shs40 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDTCCytoMed Therapeutics0.00%-23.57%-23.80%-34.87%-66.84%IMNNImunon0.00%-3.53%-12.78%-16.51%-77.67%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%VCNXVaccinex0.00%+29.99%-2.88%-15.83%+46.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDTCCytoMed Therapeutics$0.78+7.9%$1.02$0.68▼$3.68$8.56M-0.188,106 shs119,865 shsIMNNImunon$2.72-0.4%$3.01$2.52▼$41.22$10.88M2.0435,287 shs18,948 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/AVCNXVaccinex$1.01$0.98$0.31▼$1.50$2.63M1.13,345 shs40 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDTCCytoMed Therapeutics0.00%-23.57%-23.80%-34.87%-66.84%IMNNImunon0.00%-3.53%-12.78%-16.51%-77.67%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%VCNXVaccinex0.00%+29.99%-2.88%-15.83%+46.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGDTCCytoMed Therapeutics 1.00SellN/AN/AIMNNImunon 2.00Hold$132.504,771.32% UpsidePHXMPHAXIAM Therapeutics 0.00N/AN/AN/AVCNXVaccinex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCNX, GDTC, IMNN, and PHXM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$10.004/17/2026IMNNImunon Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/10/2026GDTCCytoMed Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGDTCCytoMed Therapeutics$250K36.91N/AN/A$0.45 per share1.73IMNNImunonN/AN/AN/AN/A$2.30 per shareN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/AVCNXVaccinex$388K6.77N/AN/A($2.59) per share-0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGDTCCytoMed Therapeutics-$3.10MN/AN/AN/AN/AN/AN/AN/AN/AIMNNImunon-$14.49M-$7.97N/AN/AN/AN/A-406.71%-157.02%5/12/2026 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/AN/AN/AN/AN/AN/AN/AN/AVCNXVaccinex-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%5/18/2026 (Estimated)Latest VCNX, GDTC, IMNN, and PHXM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026N/AVCNXVaccinex-$73.0380N/AN/AN/A$0.05 millionN/A5/12/2026Q1 2026IMNNImunon-$1.2150N/AN/AN/AN/AN/A3/31/2026H2 2025GDTCCytoMed TherapeuticsN/A-$0.0550N/A-$0.0550N/A$0.06 million3/31/2026Q4 2025IMNNImunon-$1.43-$1.29+$0.14-$1.30($0.73) millionN/A2/15/2026Q4 2025GDTCCytoMed TherapeuticsN/A-$0.0550N/A-$0.0550N/A$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGDTCCytoMed Therapeutics0.065.175.17IMNNImunonN/A2.322.32PHXMPHAXIAM Therapeutics0.231.78N/AVCNXVaccinexN/A0.770.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGDTCCytoMed Therapeutics0.04%IMNNImunon4.47%PHXMPHAXIAM Therapeutics0.40%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipGDTCCytoMed TherapeuticsN/AIMNNImunon5.96%PHXMPHAXIAM Therapeutics1.94%VCNXVaccinex51.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGDTCCytoMed TherapeuticsN/A11.83 millionN/ANot OptionableIMNNImunon303.98 million3.75 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataVCNXVaccinex402.60 million1.26 millionNo DataVCNX, GDTC, IMNN, and PHXM HeadlinesRecent News About These CompaniesVaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025April 29, 2026 | quiverquant.comQVaccinex Reports 2025 Annual Financial ResultsApril 29, 2026 | globenewswire.comVaccinex Inc.April 10, 2026 | barrons.comVaccinex announces $60M revenue sharing agreement with PDVDecember 23, 2025 | msn.comVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s DiseaseDecember 23, 2025 | markets.businessinsider.comVaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s TreatmentDecember 23, 2025 | quiverquant.comQVaccinex presents promising cancer treatment data at ASCOMay 29, 2025 | uk.investing.comVaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025May 29, 2025 | nasdaq.comVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingMay 27, 2025 | globenewswire.comAbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finanznachrichten.deAbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug TargetsMay 13, 2025 | finance.yahoo.comVaccinex to report new clinical data on pepinemab in enhancing immunotherapyApril 22, 2025 | markets.businessinsider.comVaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025April 21, 2025 | quiverquant.comQVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)April 21, 2025 | globenewswire.comVaccinex director resigns, no disagreement citedMarch 21, 2025 | investing.comVaccinex plans Nasdaq exit as Alzheimer market pressure growsMarch 10, 2025 | finance.yahoo.comVaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 8, 2025 | finanznachrichten.deVaccinex to delist common stock from NasdaqMarch 7, 2025 | markets.businessinsider.comVaccinex Plans to Delist its Common Stock from The Nasdaq Stock MarketMarch 7, 2025 | globenewswire.comPepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCNX, GDTC, IMNN, and PHXM Company DescriptionsCytoMed Therapeutics NASDAQ:GDTC$0.78 +0.06 (+7.85%) Closing price 05/8/2026 03:55 PM EasternExtended Trading$0.76 -0.02 (-2.05%) As of 05/8/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Imunon NASDAQ:IMNN$2.72 -0.01 (-0.37%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.76 +0.03 (+1.29%) As of 05/8/2026 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 05/8/2026PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Vaccinex NASDAQ:VCNX$1.01 0.00 (0.00%) As of 05/8/2026Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
